About the DisTinGuish Study
Trial Name: A Phase 2a, Multicenter, Open-Label Study of DKN-01 in Combination With Tislelizumab ± Chemotherapy as First-Line or Second-Line Therapy in Adult Patients With Inoperable, Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (DisTinGuish)
ClinicalTrials.gov Indentifier: NCT04363801
Completion Date: June 2023
Recruitment Status: Recruiting
Sponsor: Leap Therapeutics, Inc.
Recruitment Contact: Cynthia Sirard, MD617-714-0357 CSirard@leaptx.com
Elizabeth Parker Eparker@leaptx.com